76350 Federal Register / Vol. 71, No. 244 / Wednesday, December 20, 2006 / Notices 

promising vaccines, especially for 

children and the elderly, who are most 

likely to suffer serious consequences 

from infection. 

Application: Prevention of E. coli 

O157 infection. 

Development Status: Clinical studies 

have been performed and are described 

in Konadu et al., J Infect Dis. 1998 

Feb;177(2):383–387 and Ahmed et al., J 

Infect Dis. 2006 Feb;193(2):515–526. 

Inventors: Shousun C. Szu, Edward 

Konadu, and John B. Robbins (NICHD). 

Patent Status: U.S. Patent 6,858,211 

issued 22 Feb 2005 (HHS Reference No. 

E–158–1998/0–US–06); U.S. Patent 

Application No. 10/987,428 filed 12 

Nov 2004 (HHS Reference No. E–158–

1998/0–US–07). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Peter A. Soukas, 

J.D.; 301/435–4646; 

soukasp@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Child Health 

and Human Development, Laboratory of 

Developmental and Molecular 

Immunity, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Vaccine for E. coli O157 

for Children and Adults. Please contact 

Betty Tong, PhD at 301–594–4263, 

tongb@mail.nih.gov for more 

information. 

Dated: December 8, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E6–21666 Filed 12–19–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Meeting 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the National Advisory 

Council for Complementary and 

Alternative Medicine (NACCAM) 

meeting. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussion could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Complementary and Alternative 

Medicine. 

Date: February 2, 2007. 

Closed: 9 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Open: 1 p.m. to 4:30 p.m. 

Agenda: Opening remarks by the Acting 

Director of National Center for 

Complementary and Alternative Medicine, 

presentations of new research initiatives, and 

other council related business. 

Place: National Institutes of Health, 

Neuroscience Building, 6001 Executive 

Boulevard, Rooms C & D, Rockville, MD 

20852. 

Contact Person: Martin H. Goldrosen, 

Executive Secretary, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892. (301) 594–2014. 

The public comments session is scheduled 

from 4–4:30 p.m., but could change 

depending on the actual time spent on each 

agenda item. Each speaker will be permitted 

5 minutes for their presentation. Interested 

individuals and representatives of 

organizations are requested to notify Dr. 

Martin H. Goldrosen, National Center for 

Complementary and Alternative Medicine, 

NIH, 6707 Democracy Boulevard, Suite 401, 

Bethesda, Maryland 20892, 301–594–2014, 

Fax: 301–480–9970. Letters of intent to 

present comments, along with a brief 

description of the organization represented, 

should be received no later than 5 p.m. on 

January 31, 2007. Only one representative of 

an organization may present oral comments. 

Any person attending the meeting who does 

not request an opportunity to speak in 

advance of the meeting may be considered 

for oral presentation, if time permits, and at 

the discretion of the Chairperson. In 

addition, written comments may be 

submitted to Dr. Martin H. Goldrosen at the 

address listed above up to ten calendar days 

(February 12, 2007) following the meeting. 

Copies of the meeting agenda and roster of 

members will be furnished upon request by 

contacting Dr. Martin H. Goldrosen, 

Executive Secretary, NACCAM, National 

Center for Complementary and Alternative 

Medicine, National Institutes of Health, 6707 

Democracy Boulevard, Suite 401, Bethesda, 

Maryland 20892, 301–594–2014, Fax 301–

480–9970, or via e-mail at 

naccames@mail.nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

into the building by nongovernment 

employees. Persons without a government 

I.D. will need to show a photo I.D. and signin at the security desk upon entering the 

building. 

Dated: December 13, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9773 Filed 12–19–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of meetings of the 

National Advisory Allergy and 

Infectious Diseases Council. 

The meetings will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Allergy and Infectious Diseases Council. 

Date: January 29, 2007. 

Open: 10:30 a.m. to 11:40 a.m. 

Agenda: Report from the Institute Director 

and the Director of Center for Scientific 

Research. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, 

Conference Rooms E1/E2, Bethesda, MD 

20892. 

Closed: 11:40 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, 

Conference Rooms E1/E2, Bethesda, MD 

20892. 

Contact Person: Paula S. Strickland, 

Extramural Science Administrator for Special 


sroberts on PROD1PC70 with NOTICES